Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

NEW YORK, January 1, 2026, 10:46 ET — Market closed.

  • Regencell Bioscience Holdings last closed down 8.3% at $21 on Dec. 31
  • The company’s investor updates show no new press release since Oct. 31
  • U.S. stocks are shut for New Year’s Day; macro data hits before trading resumes

Regencell Bioscience Holdings’ shares last closed down 8.3% at $21 on Wednesday, just before U.S. markets shut for the New Year’s Day holiday. New York Stock Exchange

The latest swing underlined the stock’s extreme volatility: Nasdaq data show a 52-week range spanning roughly $0.09 to $83.60. Nasdaq

That matters now because the move came without an obvious company-specific catalyst in the past day, leaving traders to focus on liquidity and positioning into the first session after the holiday. The company’s investor-relations site lists its most recent press release as Oct. 31. Regencell Bioscience -

Trading was wide on the day. The stock ranged from $21.00 to $23.23 and closed at the low, with about 173,000 shares traded, market data show. Investing

Volume ran below its recent average, a reminder that relatively small orders can move the stock sharply when participation is light. The shares also remain above key moving-average levels tracked by market technicians, which some traders use as a rough read on trend. StockAnalysis

Regencell, based in Hong Kong, says it is developing Traditional Chinese Medicine (TCM) treatments — herbal-based therapies rooted in Chinese medical practice — for neurocognitive conditions including ADHD and autism spectrum disorder. StockAnalysis

Market data trackers put Regencell’s equity value at roughly $10.4 billion, with about 494 million shares outstanding. StockAnalysis

The company’s most recent annual report on Form 20-F — the SEC filing used by foreign private issuers — was filed on Oct. 31, SEC records show. SEC

Regencell last year carried out a 38-for-1 forward stock split, which increases the number of shares while lowering the price per share, in a move it said required no action by shareholders. Regencell Bioscience –

Before trading resumes, investors will parse a fresh read on U.S. factory activity: the ISM manufacturing PMI, a survey-based gauge of manufacturing conditions, is due at 10 a.m. ET on Friday. YCharts

Construction spending data are also scheduled for 10 a.m. ET the same day, according to an economic calendar, and can move rates and the dollar — inputs that often ripple through equities. Forex Trading Charts

Next week brings heavier macro catalysts, led by the U.S. jobs report for December on Jan. 9 and the consumer price index on Jan. 13, Labor Department schedules show. Bureau of Labor Statistics

Stock Market Today

  • Institutional Investors Hold 34% Stake in Nazara Technologies Amid Market Gains
    January 22, 2026, 8:31 PM EST. Institutional investors own 34% of Nazara Technologies Limited (NSE:NAZARA), underscoring their significant stake in the company's performance. Last week, the firm hit a market capitalization of ₹106 billion, rewarding these investors with substantial gains. Over the past year, Nazara's stock has returned 14%. Plutus Wealth Management LLP leads the pack with an 11% share, followed by individual investors holding notable stakes. The CEO owns 2.2% of shares, while the top 10 shareholders control over half the company's stock, balancing influence across stakeholders. Despite institutional confidence, analysts remain a key barometer for Nazara's future prospects. The absence of hedge fund ownership simplifies the shareholder structure. Institutional ownership signals credibility but also highlights potential volatility if investment sentiments shift collectively.
Costco stock today: COST at $862 as New Year’s Day shuts markets; SEC insider sale filing in focus
Previous Story

Costco stock today: COST at $862 as New Year’s Day shuts markets; SEC insider sale filing in focus

Pitney Bowes NT 43 drops 3% today as Treasury yields rise — what’s next for PBI.PRB
Next Story

Pitney Bowes NT 43 (PBI-PB) slides 6% into year-end — what investors are watching next

Go toTop